Literature DB >> 19219476

[PET and PET-CT of malignant tumors of the exocrine pancreas].

S N Reske1.   

Abstract

Adenocarcinomas of the pancreas represent the majority (>95%) of all malignant pancreatic tumors. They are formed from malignant degeneration of the exocrine part of the pancreas. Cystic acinar tumors are much rarer and originate from secretion-producing parenchymal cells of the pancreas. Endocrine tumors of the pancreas will not be dealt with in this context.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19219476     DOI： 10.1007/s00117-008-1756-0

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


  37 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Pancreatic cancer or chronic pancreatitis? An answer from PET/MRI image fusion.

Authors:  Alberto Malesci; Luca Balzarini; Arturo Chiti; Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

3.  The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.

Authors:  Seungmin Bang; Hye Won Chung; Seung Woo Park; Jae Bock Chung; Mijin Yun; Jong Doo Lee; Si Young Song
Journal:  J Clin Gastroenterol       Date:  2006 Nov-Dec       Impact factor: 3.062

4.  Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease.

Authors:  P D Shreve
Journal:  Eur J Nucl Med       Date:  1998-03

5.  Detection of liver metastases from pancreatic cancer using FDG PET.

Authors:  A Fröhlich; C G Diederichs; L Staib; J Vogel; H G Beger; S N Reske
Journal:  J Nucl Med       Date:  1999-02       Impact factor: 10.057

Review 6.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

7.  In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors.

Authors:  Ken Herrmann; Florian Eckel; Stefan Schmidt; Klemens Scheidhauer; Bernd Joachim Krause; Joerg Kleeff; Tibor Schuster; Hans-Juergen Wester; Helmut Friess; Roland M Schmid; Markus Schwaiger; Andreas K Buck
Journal:  J Nucl Med       Date:  2008-08-14       Impact factor: 10.057

8.  Positron emission tomography with 2-deoxy-2-[(18)F] fluoro- d-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion.

Authors:  Masato Yoshioka; Tsutomu Sato; Tomoki Furuya; Satoshi Shibata; Hideaki Andoh; Yoshihiro Asanuma; Jun Hatazawa; Kenji Koyama
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

9.  18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Cosimo Sperti; Sergio Bissoli; Claudio Pasquali; Laura Frison; Guido Liessi; Franca Chierichetti; Sergio Pedrazzoli
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

10.  FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis.

Authors:  Mariëtte C A van Kouwen; Jan B M J Jansen; Harry van Goor; Steve de Castro; Wim J G Oyen; Joost P H Drenth
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-11-12       Impact factor: 9.236
View more
  1 in total

1.  Emodin alleviates gemcitabine resistance in pancreatic cancer by inhibiting MDR1/P-glycoprotein and MRPs expression.

Authors:  Hongchun Guo; Feng Liu; Shuguang Yang; Tao Xue
Journal:  Oncol Lett       Date:  2020-08-27       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.